Trevi Therapeutics Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Trevi Therapeutics Stock Summary

Trevi Therapeutics competes with Cue Biopharma, AN2 Therapeutics, Bioatla, Spero Therapeutics, and Bolt Biotherapeutics. Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. Trevi Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 23 people.

Trevi Therapeutics Key Financial Ratios

Trevi Therapeutics Key Balance Sheet Accounts

Trevi Therapeutics Key Income Statement Accounts

Trevi Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Trevi Therapeutics's current stock value. Our valuation model uses many indicators to compare Trevi Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Trevi Therapeutics competition to find correlations between indicators driving Trevi Therapeutics's intrinsic value. More Info.Trevi Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . As of now, Trevi Therapeutics' Return On Equity is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Trevi Therapeutics' earnings, one of the primary drivers of an investment's value.

Trevi Therapeutics Systematic Risk

Today, most investors in Trevi Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Trevi Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Trevi Therapeutics growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Trevi Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Trevi Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Trevi Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Trevi Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Trevi Therapeutics's daily price indicators and compare them against related drivers.

When running Trevi Therapeutics' price analysis, check to measure Trevi Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Trevi Therapeutics is operating at the current time. Most of Trevi Therapeutics' value examination focuses on studying past and present price action to predict the probability of Trevi Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Trevi Therapeutics' price. Additionally, you may evaluate how the addition of Trevi Therapeutics to your portfolios can decrease your overall portfolio volatility.